These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26140603)

  • 1. From Dish to Bedside: Lessons Learned While Translating Findings from a Stem Cell Model of Disease to a Clinical Trial.
    McNeish J; Gardner JP; Wainger BJ; Woolf CJ; Eggan K
    Cell Stem Cell; 2015 Jul; 17(1):8-10. PubMed ID: 26140603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edaravone in ALS.
    Takahashi R
    Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
    [No Abstract]   [Full Text] [Related]  

  • 3. Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?
    Butsch PO; Cudkowicz ME
    Exp Neurol; 2007 Jul; 206(1):11-5. PubMed ID: 17498699
    [No Abstract]   [Full Text] [Related]  

  • 4. New Model System Offers Clues to ALS.
    Kuehn BM
    JAMA; 2011 Oct; 306(14):1534. PubMed ID: 21990293
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis.
    Lee JH; Liu JW; Lin SZ; Harn HJ; Chiou TW
    Cell Transplant; 2018 Sep; 27(9):1301-1312. PubMed ID: 30033758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.
    Cleveland DW; Rothstein JD
    Nat Rev Neurosci; 2001 Nov; 2(11):806-19. PubMed ID: 11715057
    [No Abstract]   [Full Text] [Related]  

  • 7. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.
    DeLoach A; Cozart M; Kiaei A; Kiaei M
    Expert Opin Drug Discov; 2015 Oct; 10(10):1099-118. PubMed ID: 26307158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.
    Battaglia G; Riozzi B; Bucci D; Di Menna L; Molinaro G; Pallottino S; Nicoletti F; Bruno V
    Neurobiol Dis; 2015 Feb; 74():126-36. PubMed ID: 25434487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The non-cell-autonomous component of ALS: new in vitro models and future challenges.
    Ferraiuolo L
    Biochem Soc Trans; 2014 Oct; 42(5):1270-4. PubMed ID: 25233402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy: On the treatment trail for ALS.
    Scott A
    Nature; 2017 Oct; 550(7676):S120-S121. PubMed ID: 29045376
    [No Abstract]   [Full Text] [Related]  

  • 11. A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies.
    Yamamoto M; Tanaka F; Tatsumi H; Sobue G
    Expert Opin Pharmacother; 2008 Aug; 9(11):1845-57. PubMed ID: 18627324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDNF is trophic for mouse motoneurons that express a mutant superoxide dismutase (SOD1) gene.
    Mitsumoto H
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2000 Mar; 1(2):69-70. PubMed ID: 11467052
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoxia causes autophagic stress and derangement of metabolic adaptation in a cell model of amyotrophic lateral sclerosis.
    Cimini S; Rizzardini M; Biella G; Cantoni L
    J Neurochem; 2014 May; 129(3):413-25. PubMed ID: 24359187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human superoxide dismutase 1 overexpression in motor neurons of Caenorhabditis elegans causes axon guidance defect and neurodegeneration.
    Li J; Li T; Zhang X; Tang Y; Yang J; Le W
    Neurobiol Aging; 2014 Apr; 35(4):837-46. PubMed ID: 24126158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.
    Dimos JT; Rodolfa KT; Niakan KK; Weisenthal LM; Mitsumoto H; Chung W; Croft GF; Saphier G; Leibel R; Goland R; Wichterle H; Henderson CE; Eggan K
    Science; 2008 Aug; 321(5893):1218-21. PubMed ID: 18669821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target.
    Barber SC; Shaw PJ
    Free Radic Biol Med; 2010 Mar; 48(5):629-41. PubMed ID: 19969067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation.
    Koh SH; Kim Y; Kim HY; Cho GW; Kim KS; Kim SH
    Eur J Neurosci; 2007 Apr; 25(7):1923-30. PubMed ID: 17439481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroscience: Standard model.
    Schnabel J
    Nature; 2008 Aug; 454(7205):682-5. PubMed ID: 18685674
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model.
    Marconi S; Bonaconsa M; Scambi I; Squintani GM; Rui W; Turano E; Ungaro D; D'Agostino S; Barbieri F; Angiari S; Farinazzo A; Constantin G; Del Carro U; Bonetti B; Mariotti R
    Neuroscience; 2013 Sep; 248():333-43. PubMed ID: 23727509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.